Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Ups & SMEs

Set Alert for Start-Ups & SMEs

Finance Watch: Sironax, IDRx, OriCell Reveal First VC Mega-Rounds Of August

Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing. 

Financing StartUps and SMEs

Newly Launched Replay Has Big Plans For Writing and Delivering ‘Big DNA’

With a hub-and-spoke model, Replay has ambitious plans to solve multiple problems in genetic medicine and to disrupt the current AAV gene therapy model.

Companies Gene Therapy

Finance Watch: VC Fundraising Dips In Q2, But Mega-Deal Pace Is Strong

Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.

Financing Innovation

Ex-GSK Leader Launches ‘Molecular Clamp’ Vaccine Company Vicebio

Venture capital firm Medicxi has chosen Emmanuel Hanon to lead the company, hiring two more ex-GSK veterans to create what they hope is a ‘dream team’ in vaccines.

Commercial Companies

Finance Watch: Big Money For Private Biopharma As Start-Up Areteia Raises $350m

Private Company Edition: As venture capital funding continues at a robust pace relative to public company financings, Knopp Biosciences and Population Health Partners launched Areteia with enough cash to fund Phase III asthma trials and Qiming revealed new VC funds totaling $2.5bn and $700m.

Financing Innovation

Spain's Oryzon Bucks Trend To Seek NASDAQ Listing

The year to date has been a depressing period for initial public offerings, especially in Europe, but the Madrid-based epigenetics specialist is evaluating whether to head west and list in the US.


Financing Business Strategies

Finance Watch: Public Market Doldrums Have Not Sunk Private Company Funding Yet

ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on. 

Financing Business Strategies

ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund

ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups. 

Financing Innovation

ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines

The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.

Financing Business Strategies

4D Pharma Is Latest Biotech Casualty After Creditor Calls Time

The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.

Companies Commercial

Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds

Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.

Financing Innovation

Third Rock Thinks Its Model Reassures Investors In Difficult Times

New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.

Financing Business Strategies
See All
UsernamePublicRestriction

Register